BioSpace News Archive

New executives part of Company’s strategic plans to expand market footprint and raise awareness of key ‘physician spend’ problem hospitals face.

Group Aims to Bring Disease-Associated Biomarker Through FDA’s Drug Development Tools Qualification Program

Keynote speakers are Dr. Eric Topol, executive vice president of The Scripps Research Institute and Jeff Stibel, vice chairman of Dun & Bradstreet

Weekend Unlimited Inc. announced that CEO Mr. Paul Chu spoke at New York City’s CannaGather event on Tuesday, March 20.

Dr. Lieu brings expansive clinical development expertise as NGM continues to advance its broad, diverse clinical portfolio

Eos Biosciences, Inc. announced that the U.S. Patent and Trademark Office has granted Eos Biosciences Patent No. 10,183,078, relating to a novel approach of using HER3-targeted Eosomes as a shuttle system for transporting various classes of therapeutics across the blood-brain barrier for treatment of brain disorders, including brain cancer.

Epic Sciences, Inc. announced that the New York State Department of Health has completed licensure to provide the Oncotype DX® AR-V7 Nucleus Detect™ test for patients with metastatic castration-resistant prostate cancer.

Data presented at the European Association of Urology showed the ProSense™ system at 1-year follow-up was safe, effective and without serious adverse events for treating small kidney tumors

EFA develops a revolutionary accurate portable diagnostic system for real-time testing and disease mapping in which the first application to the market will be conducting blood counts and other examinations, using blood sample.

Cesca Therapeutics Inc. announced that the Company will release its financial results for the fourth quarter ended December 31, 2018 on Monday, March 25, 2019 after close of trading.